Palynziq (Pegvaliase): Uses, Dosage & Side Effects
Enzyme replacement therapy for phenylketonuria (PKU) in adults
Quick Facts About Palynziq
Key Takeaways
- Palynziq is the first enzyme substitution therapy approved for phenylketonuria (PKU) in adults who cannot adequately control blood phenylalanine levels through diet alone.
- Treatment involves subcutaneous injections starting at 2.5 mg once weekly, with gradual dose escalation to a typical maintenance dose of 20–60 mg daily.
- Anaphylaxis is a known risk – patients must always carry an epinephrine auto-injector and have an observer present during the first 6 months of self-injection.
- Most patients achieve a meaningful reduction in blood phenylalanine within 18 months, though some may require up to 30 months to respond.
- Common side effects include injection site reactions, joint pain, headache, nausea, and allergic reactions – pre-medication with paracetamol and antihistamines helps reduce symptoms.
What Is Palynziq and What Is It Used For?
Palynziq contains the active substance pegvaliase, a PEGylated (polyethylene glycol-conjugated) form of the enzyme phenylalanine ammonia lyase (PAL). This enzyme provides an alternative metabolic pathway for breaking down phenylalanine, converting it into ammonia and trans-cinnamic acid – both of which are harmlessly eliminated by the body. By reducing circulating phenylalanine levels, Palynziq addresses the fundamental metabolic deficiency that underlies PKU.
Phenylketonuria is a rare inherited metabolic disorder caused by mutations in the gene encoding phenylalanine hydroxylase (PAH), the liver enzyme normally responsible for converting phenylalanine to tyrosine. When PAH activity is absent or severely deficient, phenylalanine accumulates in the blood and brain, leading to a range of neurological and psychiatric complications including intellectual disability, seizures, executive dysfunction, anxiety, depression, and attention deficits. Left untreated from birth, classic PKU can cause profound intellectual disability.
The traditional cornerstone of PKU management is a strict low-phenylalanine diet, supplemented with medical formula to provide essential amino acids and nutrients. However, many adults with PKU find lifelong dietary adherence extremely challenging. Studies consistently show that a significant proportion of adults with PKU have blood phenylalanine levels well above the recommended therapeutic range, putting them at risk for ongoing neuropsychological difficulties. Palynziq offers these patients an additional treatment option when dietary management alone is insufficient.
Palynziq was approved by the European Medicines Agency (EMA) in 2019 and by the US Food and Drug Administration (FDA) in 2018 under the brand name Palynziq. It represented a paradigm shift in PKU treatment as the first enzyme substitution therapy for this condition, offering patients a pharmacological tool to lower phenylalanine levels beyond what diet restriction alone can achieve.
Clinical trials (PRISM-1 and PRISM-2) demonstrated that Palynziq significantly reduced blood phenylalanine concentrations in adults with PKU. In the pivotal Phase 3 PRISM-2 trial, patients receiving Palynziq achieved a mean reduction in blood phenylalanine of approximately 51% from baseline, with many patients reaching levels within the recommended therapeutic range of 120–600 micromol/L.
What Should You Know Before Taking Palynziq?
Contraindications
Palynziq must not be used if you have a severe allergy (hypersensitivity) to pegvaliase or any of the other ingredients in the medicine. Importantly, it is also contraindicated in patients with a known severe allergy to any other medicine containing polyethylene glycol (PEG), as the PEGylation component of pegvaliase may trigger cross-reactive immune responses. PEG is found in a variety of pharmaceutical products including certain laxatives, injectable medications, and some cosmetic preparations, so patients should disclose all known allergies to their healthcare provider before initiating therapy.
If you are unable or unwilling to use an epinephrine auto-injector for the treatment of severe allergic reactions, you must inform your doctor before starting treatment, as this safety requirement is fundamental to the Palynziq treatment programme.
Warnings and Precautions
Palynziq can cause severe allergic reactions (anaphylaxis) that may be life-threatening. These reactions can occur at any time after injection, regardless of how long you have been on treatment. Always carry your epinephrine auto-injector. If you experience swelling of the face, throat or tongue, difficulty breathing, rapid heartbeat, dizziness, or widespread hives – use your epinephrine immediately and call emergency services.
Allergic reactions are very common during Palynziq treatment, affecting more than 1 in 10 patients. The severity ranges from mild injection site reactions to life-threatening anaphylaxis. Your healthcare provider will prescribe pre-medications – typically paracetamol (acetaminophen), fexofenadine (an antihistamine), and/or ranitidine (an H2 blocker) – to be taken before each injection to help mitigate allergic symptoms.
During at least the first 6 months of self-injection, an observer must be present when you inject Palynziq and must remain with you for at least 1 hour afterwards. The observer should be trained to recognise signs and symptoms of severe allergic reactions and know how to administer epinephrine. Your doctor will advise whether observation needs to continue beyond 6 months based on your individual response to treatment.
If you experience a severe allergic reaction, do not continue using Palynziq until you have consulted with your prescribing physician. Your doctor will determine whether it is safe for you to resume treatment. Signs and symptoms requiring immediate medical attention include:
- Swelling of the face, eyes, lips, mouth, throat, tongue, hands, or feet
- Difficulty breathing or wheezing
- Throat tightness or a choking sensation
- Difficulty swallowing or speaking
- Dizziness or fainting
- Loss of bladder or bowel control
- Rapid heartbeat
- Rapidly spreading hives (urticaria)
- Flushing
- Severe abdominal pain, cramping, vomiting, or diarrhoea
PEG-Containing Medications
Palynziq contains polyethylene glycol (PEG) as part of its molecular structure. If you are receiving any other injectable medication that also contains PEG – for example, pegylated medroxyprogesterone acetate – there is an increased risk of allergic reactions. You should inform your doctor or pharmacist about all injectable medications you are currently using, have recently used, or may use in the future.
Low Blood Phenylalanine Levels
During treatment with Palynziq, your blood phenylalanine levels may drop below the normal range. Phenylalanine is an essential amino acid, and excessively low levels (hypophenylalaninaemia) can cause their own set of problems, particularly during pregnancy. Your doctor will monitor your blood phenylalanine levels monthly. If levels become too low, your doctor may adjust your diet (by increasing protein intake) and/or reduce your Palynziq dose. Phenylalanine levels will be checked every two weeks until they return to the normal range.
Time to Response
The dose of Palynziq is increased gradually, starting low and being titrated upward over time. This cautious approach is necessary to allow the immune system to adapt to the enzyme and to minimise hypersensitivity reactions. Most patients respond within 18 months of starting treatment, but it can sometimes take up to 30 months to find the optimal dose that effectively lowers blood phenylalanine into the target range.
Pregnancy and Breastfeeding
Palynziq is not recommended during pregnancy unless the condition requires treatment and other methods of controlling phenylalanine levels are inadequate. Both excessively high and excessively low phenylalanine levels during pregnancy can harm the mother and the developing baby. Maternal PKU syndrome, caused by uncontrolled high phenylalanine during pregnancy, can result in congenital heart defects, microcephaly, intellectual disability, and growth restriction in the child. Conversely, animal studies suggest that abnormally low phenylalanine levels may impair fertility and fetal development.
It is not known whether Palynziq is excreted in breast milk or whether it could affect a nursing infant. Patients should discuss the best approach to infant feeding with their healthcare provider if they are using Palynziq.
The effects of Palynziq on human fertility have not been established. Animal studies suggest that females may have difficulty becoming pregnant if phenylalanine levels are abnormally low. Women of childbearing potential should discuss contraception and family planning with their healthcare provider before and during treatment.
Children and Adolescents
The safety and efficacy of Palynziq in children and adolescents under 16 years of age have not been established. Therefore, this medicine should not be used in patients younger than 16 years. Clinical trials are ongoing to evaluate the potential use of Palynziq in younger age groups.
Driving and Operating Machinery
Palynziq may affect your ability to drive and operate machinery if you experience a severe allergic reaction. Patients should be cautious, particularly in the hours following injection when anaphylaxis is most likely to occur.
How Does Palynziq Interact with Other Drugs?
Palynziq has a relatively narrow interaction profile compared to many other medications, largely because it acts as an enzyme in the subcutaneous tissue and is metabolised through proteolytic degradation rather than hepatic cytochrome P450 enzymes. However, certain interactions and considerations warrant attention.
You should tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take. This includes prescription medicines, over-the-counter preparations, herbal products, and dietary supplements.
| Interacting Drug/Class | Type | Effect | Recommendation |
|---|---|---|---|
| PEG-containing injectable drugs (e.g. pegylated medroxyprogesterone) | Immunological | Increased risk of allergic/anaphylactic reactions due to anti-PEG antibodies | Avoid concomitant use; discuss alternatives with your doctor |
| Other PEGylated therapies (e.g. pegfilgrastim, peginterferon) | Immunological | Potential cross-reactivity and reduced efficacy of both agents | Monitor closely; consider alternative non-PEGylated formulations |
| Methotrexate and other immunosuppressants | Pharmacodynamic | May theoretically reduce immunogenicity and hypersensitivity reactions but also potentially alter efficacy | No formal studies; discuss risk-benefit with your doctor |
| Sapropterin (Kuvan) | Pharmacodynamic | Both lower phenylalanine – combined use increases risk of hypophenylalaninaemia | Not typically used together; monitor phenylalanine levels closely if co-administered |
Unlike many conventional medications, Palynziq does not undergo hepatic metabolism and is not expected to interact with drugs metabolised by cytochrome P450 enzymes. The primary immunological interaction concern relates to anti-PEG antibody formation, which can develop during Palynziq treatment and theoretically affect the pharmacokinetics and safety of other PEGylated medicines.
What Is the Correct Dosage of Palynziq?
Palynziq must always be used exactly as your doctor has prescribed. The dosing regimen involves a careful, individualised titration from a low starting dose to the optimal maintenance dose, which may take many months to achieve. This gradual approach is essential to minimise hypersensitivity reactions and allow the body to develop immune tolerance to the enzyme.
Adults (16 years and older)
Induction Phase
Treatment begins with 2.5 mg once weekly (white plunger syringe) for at least 4 weeks. Your doctor will then gradually increase both the dose and the injection frequency based on your tolerance and blood phenylalanine response.
Titration Phase
The dose is increased stepwise through intermediate levels: 2.5 mg twice weekly, then 10 mg once weekly (green plunger syringe), 10 mg twice weekly, 10 mg four times weekly, and 10 mg daily. Each step is maintained for a minimum period before further escalation.
Maintenance Phase
The target is a daily dose that maintains blood phenylalanine within the range of 120–600 micromol/L. Most patients reach a maintenance dose of 20 mg, 40 mg, or 60 mg daily (blue plunger syringe, 20 mg). For doses above 20 mg, multiple injections are given at the same time, with injection sites at least 5 cm apart.
| Dose & Frequency | Syringe | Minimum Duration | Notes |
|---|---|---|---|
| 2.5 mg once weekly | White plunger (2.5 mg) | 4 weeks | Starting dose for all patients |
| 2.5 mg twice weekly | White plunger (2.5 mg) | As directed | First dose increase |
| 10 mg once weekly | Green plunger (10 mg) | As directed | Intermediate step |
| 10 mg twice weekly | Green plunger (10 mg) | As directed | Intermediate step |
| 10 mg four times weekly | Green plunger (10 mg) | As directed | Intermediate step |
| 10 mg daily | Green plunger (10 mg) | As directed | Intermediate step |
| 20 mg daily | Blue plunger (20 mg) | Maintenance | Common maintenance dose |
| 40 mg daily | 2 × Blue plunger (20 mg) | Maintenance | Both injections given simultaneously; sites ≥5 cm apart |
| 60 mg daily | 3 × Blue plunger (20 mg) | Maintenance | All injections given simultaneously; sites ≥5 cm apart |
Children
Palynziq is not approved for use in children and adolescents under 16 years of age. The safety and efficacy in this population have not been established, and no dosing recommendations can be made for paediatric patients.
Elderly Patients
There is limited clinical experience with Palynziq in patients over 65 years of age. No specific dose adjustment is recommended based on age alone. However, elderly patients may be more susceptible to adverse effects and should be monitored carefully during treatment, particularly for signs of allergic reactions and cardiovascular complications associated with anaphylaxis.
Missed Dose
If you miss a dose of Palynziq, take the next dose at the scheduled time. Do not take a double dose to make up for the missed injection. Simply continue with your regular dosing schedule. If you have questions about missed doses, contact your healthcare provider.
Overdose
If you have used more Palynziq than prescribed, contact your doctor immediately. In clinical studies, doses up to 75 mg daily have been administered. Overdose may result in excessively low blood phenylalanine levels (hypophenylalaninaemia) or an increased risk of hypersensitivity reactions. Treatment is supportive and symptomatic. Monitor phenylalanine levels and adjust dietary protein intake as needed.
Stopping Treatment
If you stop taking Palynziq, your blood phenylalanine levels will likely increase back to pre-treatment levels. Do not discontinue treatment without consulting your doctor. A gradual return to stricter dietary management may be necessary to maintain phenylalanine control after stopping Palynziq.
What Are the Side Effects of Palynziq?
Like all medicines, Palynziq can cause side effects, although not everyone experiences them. Allergic reactions are the most clinically significant category of adverse events and range from mild (localised skin reactions) to life-threatening (anaphylaxis). Your doctor will monitor you closely, especially during the first months of treatment, and will prescribe pre-medications to help manage these reactions.
Anaphylaxis (common – may affect up to 1 in 10 people): Stop injecting Palynziq and use your epinephrine auto-injector immediately if you experience sudden swelling of the face or throat, difficulty breathing, rapid heartbeat, widespread hives, dizziness, or severe abdominal pain. Call emergency services immediately.
Serum sickness-type reactions (common): Contact your doctor immediately if you develop a combination of fever, rash, muscle pain, and joint pain.
Very Common
- Injection site reactions (redness, swelling, bruising, tenderness, pain)
- Joint pain (arthralgia)
- Allergic reactions (various severity)
- Low blood phenylalanine levels (hypophenylalaninaemia)
- Headache
- Skin rash
- Abdominal pain
- Nausea
- Vomiting
- Hives (urticaria)
- Itching (pruritus)
- Hair thinning or hair loss
- Cough
- Raised C-reactive protein (CRP) levels
- Decreased complement C3 and C4 proteins
- Swollen lymph nodes
- Skin redness (erythema)
- Muscle pain (myalgia)
Common
- Anaphylaxis (severe allergic reaction)
- Serum sickness-type reaction (fever, rash, joint and muscle pain)
- Joint stiffness
- Joint swelling
- Muscle stiffness
- Papular rash (small bumps on the skin)
- Skin peeling or blistering
The immunological profile of side effects is characteristic of Palynziq therapy. Because pegvaliase is a foreign protein, the immune system mounts a response that typically peaks during the first months of treatment and gradually diminishes over time as immune tolerance develops. Injection site reactions tend to be most pronounced during the early titration phase and often improve with continued treatment.
Decreases in complement proteins (C3 and C4) and elevations in C-reactive protein are immunological markers that reflect the body’s immune response to the enzyme. These laboratory changes are generally not associated with clinical symptoms but are monitored by healthcare providers as part of routine treatment surveillance.
Hair thinning or hair loss has been reported in some patients and is thought to be related to nutritional changes, particularly when blood phenylalanine levels drop rapidly. Ensuring adequate protein and nutrient intake under the guidance of a metabolic dietitian may help mitigate this effect.
It is important to report suspected adverse reactions after the medicine has been authorised. This allows continuous monitoring of the benefit-risk balance. Healthcare professionals and patients can report adverse reactions through their national reporting system (e.g. the Yellow Card scheme in the UK, MedWatch in the US, or EudraVigilance in the EU).
How Should You Store Palynziq?
Proper storage of Palynziq is essential to maintain the integrity and efficacy of the medication. As a biological product containing an enzyme, it is sensitive to temperature extremes and improper handling. Follow these storage guidelines carefully:
- Refrigerated storage: Keep Palynziq in its sealed tray in a refrigerator at 2–8°C (36–46°F). This is the preferred long-term storage condition.
- Do not freeze: Freezing will damage the protein structure of the enzyme and render the medication ineffective. If a syringe has been frozen, do not use it.
- Room temperature storage: If needed, the sealed tray may be stored at room temperature (below 25°C / 77°F) for a single period of up to 30 days, protected from heat sources. Record the date when the product was removed from the refrigerator on the unopened tray.
- Do not return to refrigerator: Once removed from the refrigerator, the product must not be placed back in refrigerated storage.
- Protect from light and heat: Keep the syringe in its sealed tray until ready for use. Avoid direct sunlight and heat sources.
- Check before use: Do not use the pre-filled syringe if it appears damaged, or if the solution is discoloured, cloudy, or contains visible particles. The solution should be clear to slightly opalescent and colourless to pale yellow.
- Expiry date: Do not use after the expiry date stated on the syringe label, tray, and carton (marked “EXP”). The expiry date refers to the last day of that month.
- Keep out of reach of children.
Used syringes should be placed immediately into a sharps disposal container. Do not dispose of syringes in household waste or via the sewage system. Ask your pharmacist about appropriate disposal of medicines and sharps containers that are no longer needed.
What Does Palynziq Contain?
Palynziq is supplied as a clear to slightly opalescent, colourless to pale yellow solution for subcutaneous injection. It is available in three strengths, each in a pre-filled syringe with an automatic needle shield:
| Strength | Volume | Plunger Colour | Pack Size |
|---|---|---|---|
| 2.5 mg | 0.5 mL | White | 1 pre-filled syringe |
| 10 mg | 0.5 mL | Green | 1 pre-filled syringe |
| 20 mg | 1 mL | Blue | 1 or 10 pre-filled syringes |
Inactive Ingredients (Excipients)
- Trometamol – buffer agent to maintain pH stability
- Trometamol hydrochloride – buffer agent
- Sodium chloride – tonicity agent (this medicine contains less than 1 mmol / 23 mg sodium per pre-filled syringe, essentially “sodium-free”)
- Trans-cinnamic acid – stabiliser
- Water for injections – solvent
The marketing authorisation holder and manufacturer is BioMarin International Limited, Shanbally, Ringaskiddy, County Cork, Ireland, P43 R298.
Frequently Asked Questions About Palynziq
Palynziq (pegvaliase) is used to treat phenylketonuria (PKU) in adults aged 16 years and older. It is specifically indicated for patients whose blood phenylalanine levels cannot be maintained below 600 micromol/L with dietary management or other available treatments alone. Palynziq works by providing an alternative enzyme that breaks down phenylalanine in the body.
Palynziq is administered as a subcutaneous injection (under the skin) using a pre-filled syringe. Recommended injection sites include the middle front of the thighs and the lower abdomen (at least 5 cm from the navel). After initial training by a healthcare provider, patients can learn to self-inject. An observer must be present during self-injection for at least the first 6 months of treatment.
The most serious risk of Palynziq is anaphylaxis – a severe, potentially life-threatening allergic reaction that can occur at any time during treatment. For this reason, all patients must carry an epinephrine auto-injector at all times, and an observer must be present during and for 1 hour after self-injection for at least the first 6 months. Other serious risks include serum sickness-type reactions and excessively low phenylalanine levels.
Palynziq requires a gradual dose escalation that takes many months. Most patients see a meaningful reduction in blood phenylalanine levels within 18 months of starting treatment, though some may require up to 30 months. The slow titration process is necessary to allow the immune system to adapt to the enzyme and minimise hypersensitivity reactions. Your doctor will monitor your phenylalanine levels monthly to track your response.
Palynziq is not recommended during pregnancy unless treatment is necessary and other methods of controlling phenylalanine levels are inadequate. Maintaining appropriate phenylalanine levels is critical during pregnancy because both excessively high and excessively low levels can harm the developing baby. Women of childbearing potential should discuss family planning with their healthcare provider before and during Palynziq treatment.
Yes. During at least the first 6 months of self-injecting Palynziq, an observer must be present during the injection and for at least 1 hour afterwards. The observer should be trained to recognise signs of severe allergic reactions and know how to administer epinephrine in an emergency. Your doctor will advise if observation needs to continue beyond 6 months based on your individual response to treatment.
References
- European Medicines Agency (EMA). Palynziq (pegvaliase) – Summary of Product Characteristics. Last updated 2024. Available at: EMA – Palynziq
- US Food and Drug Administration (FDA). Palynziq (pegvaliase-pqpz) Prescribing Information. BioMarin Pharmaceutical Inc. Revised 2023.
- Longo N, Harding CO, Burton BK, et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. The Lancet. 2014;384(9937):37-44. doi:10.1016/S0140-6736(13)61841-2
- Thomas J, Levy H, Amato S, et al. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Molecular Genetics and Metabolism. 2018;124(1):27-38. doi:10.1016/j.ymgme.2018.03.006
- Harding CO, Amato RS, Stuy M, et al. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial. Molecular Genetics and Metabolism. 2018;124(1):20-26. doi:10.1016/j.ymgme.2018.03.003
- American College of Medical Genetics and Genomics (ACMG). Phenylalanine hydroxylase deficiency: Diagnosis and management guideline. Genetics in Medicine. 2014;16(2):188-200.
- van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet Journal of Rare Diseases. 2017;12(1):162. doi:10.1186/s13023-017-0685-2
- World Health Organization (WHO). Genes and Human Disease – Phenylketonuria. Available at: WHO Genomics
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians specialising in clinical pharmacology, metabolic diseases, and rare genetic disorders.
Content developed by specialist physicians with expertise in inherited metabolic disorders and enzyme replacement therapies. All medical claims are supported by peer-reviewed evidence and international treatment guidelines.
Independently reviewed by the iMedic Medical Review Board according to EMA, FDA, and ACMG guidelines. Evidence level: 1A (systematic reviews and randomised controlled trials). Last reviewed: .
iMedic follows strict editorial standards with no commercial funding or pharmaceutical company sponsorship. All content is based on the GRADE evidence framework and adheres to international medical guidelines. For more information, see our Editorial Standards page.